Specifically, its “tumor-targeting arm”—an anti-EGFR single-chain antibody fragment—selectively binds to EGFR on cSCC Tumor Cells, effectively anchoring T cells in close proximity to the Tumor Cells and minimizing off-target activation in non-tumor tissues (123). Here, EGFR is linked to neoplasm.